Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)

Summary

Eligible patients have multiple myeloma with measurable disease in the blood and a targetable soft tissue or bony lesion with radiotherapy. All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy, 6 Gy x 5 fractions, to a targetable lesion. Immunotherapy treatment starts with the first radiotherapy fraction. Nivolumab will be given every 2 weeks. Patients will have specified laboratory values measured bi-monthly and evaluated for response at 12 weeks as defined by International Myeloma Working Group Criteria. Patients will continue to receive their respective immunotherapy until disease progression or dose limiting toxicity is reached.

Timeline

Start

2018-10-23

Primary completion

2020-01-09

Completion

2020-01-16

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of patient accruals.”

Drugs

Indications